ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2014

The Role of Orosomucoid 2 in the Regulation of Bone Remodeling by Inhibiting Osteoclastogenesis and Promoting Osteogenesis

CHONG HYUK CHUNG1, Myeung-Su Lee1 and Chang-hoon Lee2, 1Wonkwang University Hospital, Iksan, South Korea, 2Wonkwang University Hospital, Iksan Jeonbuk, South Korea

Meeting: ACR Convergence 2023

Keywords: osteoblast, osteoclast, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Orosomucoid (ORM) is one of the acute phase reactant protein family and is expressed in hepatocytes and secreted into plasma under stress conditions such as tissue injury, infection, and inflammation. Three types of ORM are known to date (ORM1, 2 and 3), and ORM2 is mainly expressed in bone marrow cells. ORM2 has only some studies on hepatic metabolism, inflammation and immune regulation, and no studies on bone metabolism have been reported. The aim of this study is to reveal the role of ORM2 in the differentiation and function of osteoclasts and osteoblasts

Methods: To determine the effect of ORM2 on RANKL-induced osteoclast differentiation and function, we performed TRAP staining, F-actin stating, and bone resorbing assay using ORM2 recombinant protein or ORM2 siRNA. Also, the effect of ORM2 on osteogenesis was confirmed by ALP and ARS assay. The intracellular mechanisms responsible for the dual regulation of osteoclastogenesis and osteogenesis of ORM2 were revealed by western blotting and quantitative real-time RT-PCR.

Results: We found that ORM2 is a potential target for osteoporosis therapeutics, as treatment with this agent enhances osteoblast differentiation and bone growth and suppresses osteoclast differentiation and bone resorption by performing gain- and loss-of-function studies. During ORM2-mediated regulation of osteoclastogenesis, phosphorylation of early signal transducers such as p38, JNK, Akt, IB, PLC2, and Btk was affected, which in turn altered the mRNA and protein levels of c-Fos and NFATc1. ORM2 also increased ALP, Alizarin Red-mineralization activity, and the expression of osteoblastogenic gene markers, such as Runx2, osteocalcin (OCN), and ALP in mouse calvarial primary osteoblasts, and activated the p38-Runx2 pathway, which enhanced osteoblast differentiation.

Conclusion: we suggest that ORM2 may be a promising candidate for gene therapy for bone metabolic diseases, and further serve as a potentially important biomarker in the field of bone disease diagnosis.

Supporting image 1

ORM2 expression was increased during RANKL-induced osteoclast differentiation and the administration of recombinant ORM2 protein restrained the formation of osteoclast and bone resorption function.

Supporting image 2

The knock down of ORM2 improved osteoclast differentiation and bone resorbing function.

Supporting image 3

The knock down of ORM2 leaded to osteoclast differentiation by increasing RANKL-mediated MAPKs (ERK, JNK), NF-KB, Akt and Btk-PLCr2 calcium signaling.


Disclosures: C. CHUNG: None; M. Lee: None; C. Lee: None.

To cite this abstract in AMA style:

CHUNG C, Lee M, Lee C. The Role of Orosomucoid 2 in the Regulation of Bone Remodeling by Inhibiting Osteoclastogenesis and Promoting Osteogenesis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-role-of-orosomucoid-2-in-the-regulation-of-bone-remodeling-by-inhibiting-osteoclastogenesis-and-promoting-osteogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-orosomucoid-2-in-the-regulation-of-bone-remodeling-by-inhibiting-osteoclastogenesis-and-promoting-osteogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology